Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intercept Pharmaceuticals, Inc. - Common Stock (NQ:ICPT)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Intercept Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst
Gilead's acquisition of CymaBay Therapeutics for $4.3 billion strengthens its liver disease portfolio. Analysts see potential in seladelpar's impact on PBC and pruritus, projecting peak sales of $800... 
Via Benzinga
Top 5 Health Care Stocks That Should Keep You Up At Night
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Stocks to Sell: 7 Overbought Companies You Ought to Dump Right Now
Overbought stocks are an early indication of a potential correction on a stock; act now if you hold these stocks. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Analyst Expectations for Intercept Pharma's Future
Via Benzinga
Analyst Ratings for Intercept Pharma
Via Benzinga
Expert Ratings for Intercept Pharma
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
Via Benzinga
Why Intercept Pharmaceuticals Stock Is Skyrocketing Today
Intercept is on track to be acquired by Alfasigma at a significant premium compared to recent prices. 
Via The Motley Fool
Why Is Intercept Pharmaceuticals (ICPT) Stock Up 75% Today?
Although Intercept Pharmaceuticals popped higher on a buyout deal, many stakeholders of ICPT stock are left wondering what might have been. 
Via InvestorPlace
Why Madrigal Pharmaceuticals Stock Is Marching Higher Today
Two key tailwinds appear to be lifting the stock today. 
Via The Motley Fool
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi... 
Via Benzinga
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Tumbles 150 Points; US House Prices Rise in July
U.S. stocks traded lower this morning, with the Dow Jones falling around 150 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.45% to 33,852.58 while the NASDAQ fell 0.74%... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Rare Liver Disease Focused Intercept Pharmaceuticals Stock Trading Higher Today?
Italy-based Alfasigma has agreed to acquire Intercept Pharmaceuticals Inc (NASDAQ: ICPT) for  
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Flux Power Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers MicroAlgo Inc. (NASDAQ: MLGO) shares jumped 74% to $7.02 after it unveiled a knowledge-enhanced backtracking search algorithm to boost the performance and efficiency of research institutions. 
Via Benzinga
Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease
Thursday, CymaBay Therapeutics Inc (NASDAQ: CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar on clinical outcomes in patients with compensated cirrhosis due... 
Via Benzinga
Why CymaBay Therapeutics Stock Is Jumping Today
The momentum continues after CymaBay reported great clinical results on Thursday. 
Via The Motley Fool
Why CymaBay, With 172% Growth This Year, Just Surged For A Second Day Running
The company is working on a treatment for a liver disease that can cause severe itching. 
Via Investor's Business Daily
Intercept Pharma Gets Double Upgrade: Analyst Says OCA Combo Therapy Can Extend PBC Business
HC Wainwright has upgraded Intercept Pharmaceuticals Inc (NASDAQ: ICPT) to Buy from Sell, with a price target of  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2023
Via Benzinga
Madrigal Stock Pops As It Makes Inroads Into What Could Be A $160 Billion Market
Madrigal is working on gaining FDA approval for what could be the first NASH treatment. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2023
Via Benzinga
Former Wall Street Darling Intercept Restructures After FDA Rejects Its Liver Drug
Following the FDA rejection, Intercept will restructure to focus on rare liver diseases. 
Via Investor's Business Daily
FDA Strikes Out Intercept Pharma's Obeticholic Acid Application For NASH Patients, Focus Shifts To Rare Liver Diseases
FDA issued a Complete Response Letter to Intercept Pharmaceuticals Inc's (NASDAQ: ICPT) marketing application seeking approval for obeticholic acid (OCA) for  
Via Benzinga
New Data Shows Intercept's Fixed Dose Obeticholic Acid Combo Normalize Multiple Biomarkers In Liver Disease
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) announced initial results from a planned interim analysis of its ongoing Phase 2 study 747-213, an active comparator trial demonstrating the therapeutic... 
Via Benzinga
Top 5 Health Care Stocks That Could Blast Off In May
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.